Literature Collection

Magnifying Glass
Collection Insights

11K+

References

9K+

Articles

1500+

Grey Literature

4600+

Opioids & SU

The Literature Collection contains over 11,000 references for published and grey literature on the integration of behavioral health and primary care. Learn More

Use the Search feature below to find references for your terms across the entire Literature Collection, or limit your searches by Authors, Keywords, or Titles and by Year, Type, or Topic. View your search results as displayed, or use the options to: Show more references per page; Sort references by Title or Date; and Refine your search criteria. Expand an individual reference to View Details. Full-text access to the literature may be available through a link to PubMed, a DOI, or a URL. References may also be exported for use in bibliographic software (e.g., EndNote, RefWorks, Zotero).

Enter Search Term(s)
Year
Sort by
Order
Show
11248 Results
6921
Opioid Use Disorder Treatment Decision Making And Care Navigation Upon Release From Prison: A Feasibility Study
Type: Journal Article
Authors: Caleb J. Banta-Green, Anthony S. Floyd, Kristin Vick, Jen Arthur, Theresa J. Hoeft, Judith I. Tsui
Year: 2019
Topic(s):
Healthcare Disparities See topic collection
,
Opioids & Substance Use See topic collection
6922
Opioid use disorder treatment for people experiencing homelessness: A scoping review
Type: Journal Article
Authors: Matthew F. McLaughlin, Rick Li, Nicolás Domínguez Carrero, Paul A. Bain, Avik Chatterjee
Year: 2021
Topic(s):
Healthcare Disparities See topic collection
,
Opioids & Substance Use See topic collection
6923
Opioid use disorder treatment in rural settings: The primary care perspective
Type: Journal Article
Authors: V. S. Harder, A. C. Villanti, S. H. Heil, M. L. Smith, D. E. Gaalema, M. C. Meyer, N. H. Schafrick, S. C. Sigmon
Year: 2021
Topic(s):
Education & Workforce See topic collection
,
Healthcare Disparities See topic collection
,
Opioids & Substance Use See topic collection
6924
Opioid Use Disorder, Stigma, and Transplantation: A Call to Action
Type: Journal Article
Authors: Sarah E. Wakeman, Keren Ladin, Tim Brennan, Raymond T. Chung
Year: 2018
Publication Place: United States
Abstract:

More than 2 million Americans have an opioid use disorder (OUD). Although untreated OUD is devastating, most persons who are treated achieve remission, particularly with opioid agonist therapy (OAT), which includes such medications as methadone and buprenorphine. Each year, 12.5 million buprenorphine prescriptions are filled in the United States and 350 000 persons receive methadone (1, 2). This growing population has unique health needs, with higher prevalence of conditions that may require organ transplant, such as hepatitis C. Yet, persons with OUD may be deemed ineligible for transplant, even when they are successfully treated with OAT (3, 4).

Topic(s):
Healthcare Disparities See topic collection
,
Opioids & Substance Use See topic collection
6925
Opioid use disorder: Calling pharmacists to action for better preconception and pregnancy care
Type: Journal Article
Authors: Julia D. Muzzy Williamson, Natalie DiPietro Mager, David Bright, Justin W. Cole
Year: 2022
Topic(s):
Opioids & Substance Use See topic collection
,
Healthcare Disparities See topic collection
,
Financing & Sustainability See topic collection
6926
Opioid Use Disorder: Medical Treatment Options
Type: Journal Article
Authors: D. Coffa, H. Snyder
Year: 2019
Publication Place: United States
Abstract: Opioid use disorder is highly prevalent and can be fatal. At least 2.1 million Americans 12 years and older had opioid use disorder in 2016, and approximately 47,000 Americans died from opioid overdoses in 2017. Opioid use disorder is a chronic relapsing condition, the treatment of which falls within the scope of practice of family physicians. With appropriate medication-assisted treatment, patients are more likely to enter full recovery. Methadone and buprenorphine are opioid agonists that reduce mortality, opioid use, and HIV and hepatitis C virus transmission while increasing treatment retention. Intramuscular naltrexone is not as well studied and is harder to initiate than opioid agonists because of the need to abstain for approximately one week before the first dose. However, among those who start naltrexone, it can reduce opioid use and craving. Choosing the correct medication for a given patient depends on patient preference, local availability of opioid treatment programs, anticipated effectiveness, and adverse effects. Discontinuation of pharmacotherapy increases the risk of relapse; therefore, patients should be encouraged to continue treatment indefinitely. Many patients with opioid use disorder are treated in primary care, where effective addiction treatment can be provided. Family physicians are ideally positioned to diagnose opioid use disorder, provide evidence-based treatment with buprenorphine or naltrexone, refer patients for methadone as appropriate, and lead the response to the current opioid crisis.
Topic(s):
Education & Workforce See topic collection
,
Opioids & Substance Use See topic collection
6927
Opioid Use Disorder: Treatment & Recovery
Type: Journal Article
Authors: S. Worth, K. House
Year: 2018
Publication Place: United States
Topic(s):
Opioids & Substance Use See topic collection
6928
Opioid Use Disorder: What Is Opioid Addiction?
Type: Web Resource
Authors: Providers Clinical Support System
Year: 2017
Topic(s):
Grey Literature See topic collection
,
Opioids & Substance Use See topic collection
Disclaimer:

This grey literature reference is included in the Academy's Literature Collection in keeping with our mission to gather all sources of information on integration. Grey literature is comprised of materials that are not made available through traditional publishing avenues. Often, the information from unpublished resources can be limited and the risk of bias cannot be determined.

6929
Opioid Use Disorders
Type: Journal Article
Authors: B. Sharma, A. Bruner, G. Barnett, M. Fishman
Year: 2016
Publication Place: United States
Topic(s):
Opioids & Substance Use See topic collection
,
Healthcare Disparities See topic collection
6930
Opioid Use Disorders and Pregnancy
Type: Journal Article
Authors: Amanda J. Johnson, Cresta W. Jones
Year: 2018
Publication Place: United States
Topic(s):
Healthcare Disparities See topic collection
,
Opioids & Substance Use See topic collection
6933
Opioid Use Disorders: HHS Needs Measures to Assess the Effectiveness of Efforts to Expand Access to Medication-Assisted Treatment
Type: Government Report
Authors: United States Government Accountability Office
Year: 2017
Publication Place: Washington, DC
Topic(s):
Grey Literature See topic collection
,
Healthcare Policy See topic collection
,
Opioids & Substance Use See topic collection
Disclaimer:

This grey literature reference is included in the Academy's Literature Collection in keeping with our mission to gather all sources of information on integration. Grey literature is comprised of materials that are not made available through traditional publishing avenues. Often, the information from unpublished resources can be limited and the risk of bias cannot be determined.

6934
Opioid use following the introduction of an extended-release oxycodone formulation with tamper-resistant properties: Prospective historical chart review in methadone-maintained patients
Type: Journal Article
Authors: C. Sankey, B. Setnik, Z. Harsanyi, K. Michalko, Z. Yang, P. Geoffroy
Year: 2016
Publication Place: United States
Abstract: OBJECTIVE: Emerging data are demonstrating that tamper-resistant opioids may play an important role in changing prescription opioid abuse behaviors. This study was a chart review to examine if the reformulation of OxyContin(R) into a version with tamper-resistant properties (OxyNEO(R)) had an impact on oxycodone-positive urine drug screens (UDSs) in opioid-dependent patients receiving methadone maintenance therapy (MMT). DESIGN: The historical element of this study examined 250 eligible charts from patients on MMT who had data during the time periods when only OxyContin was available (baseline period), during the transition to OxyNEO, and when only OxyNEO was available. The prospective element included an exploratory questionnaire regarding retrospective opioid use. SETTING: The study was conducted at three methadone clinics, in Oshawa, Peterborough, and Scarborough in Ontario, Canada. PARTICIPANTS: Male and female patients were eligible if they had a diagnosis of opioid dependency, received MMT, and had at least one oxycodone-positive UDS during the baseline period. INTERVENTION: This was a noninterventional study. MAIN OUTCOME MEASURE: The main outcome was the number of oxycodonepositive UDSs. RESULTS: The results demonstrated a marked reduction in oxycodone-positive UDSs that showed stepwise, statistically significant decreases during the transition and post-OxyContin periods relative to baseline. While the oxycodone-positive UDS results were decreasing, morphine-related-positive UDSs remained relatively stable during the same periods. There were no significant gender differences noted. CONCLUSIONS: The introduction of OxyNEO was associated with a statistically significant reduction in oxycodone exposure in a population of methadone-maintained patients.
Topic(s):
Opioids & Substance Use See topic collection
6937
Opioid use in indigenous populations: Indigenous perspectives and directions in culturally responsive care
Type: Journal Article
Authors: Ariel Richer, Ariel L. Roddy
Year: 2022
Topic(s):
Education & Workforce See topic collection
,
Healthcare Disparities See topic collection
,
Opioids & Substance Use See topic collection
6938
Opioid Use in Pregnancy
Type: Journal Article
Authors: A. L. Tobon, E. Habecker, A. Forray
Year: 2019
Publication Place: United States
Abstract:

PURPOSE OF REVIEW: Perinatal opioid use is a major public health problem and is associated with a number of deleterious maternal and fetal effects. We review recent evidence of perinatal outcomes and treatment of opioid use disorder (OUD) during pregnancy. RECENT FINDINGS: Opioid exposure in pregnancy is associated with multiple obstetric and neonatal adverse outcomes, with the most common being neonatal opioid withdrawal syndrome (NOWS). Treatment with buprenorphine or methadone is associated with NOWS, but neither medication appears to have significant adverse effects on early childhood development. Buprenorphine appears to be superior to methadone in terms of incidence and severity of NOWS in exposed infants. The long-term effects of opioid exposure in utero have been inconclusive, but recent longitudinal studies point to potential differences in brain morphology that may increase vulnerability to future stressors. Maintenance therapy with methadone or buprenorphine remains the standard of care for pregnant women with OUD given its consistent superiority to placebo in terms of rates of illicit drug use and pregnancy outcomes. New non-pharmacologic management options for NOWS appear promising. Future research is needed to further evaluate the effects of opioid exposure in utero and determine the optimal delivery model for maintenance therapy.

Topic(s):
Healthcare Disparities See topic collection
,
Opioids & Substance Use See topic collection
6939
Opioid Use in Pregnancy, Neonatal Abstinence Syndrome, and Childhood Outcomes: Executive Summary of a Joint Workshop by the Eunice Kennedy Shriver NICHHD, ACOG, AAP, SMFM, CDC, and the March of Dimes Foundation
Type: Journal Article
Authors: U. M. Reddy, J. M. Davis, Z. Ren, M. F. Greene, Opioid Use in Pregnancy, Neonatal Abstinence Syndrome, and Childhood Outcomes Workshop Invited Speakers
Year: 2017
Publication Place: United States
Abstract: In April 2016, the Eunice Kennedy Shriver National Institute of Child Health and Human Development invited experts to a workshop to address numerous knowledge gaps and to review the evidence for the screening and management of opioid use in pregnancy and neonatal abstinence syndrome. The rising prevalence of opioid use in pregnancy has led to a concomitant dramatic fivefold increase in neonatal abstinence syndrome over the past decade. Experts from diverse disciplines addressed research gaps in the following areas: 1) optimal screening for opioid use in pregnancy; 2) complications of pregnancy associated with opioid use; 3) appropriate treatments for pregnant women with opioid use disorders; 4) the best approaches for detecting, treating, and managing newborns with neonatal abstinence syndrome; and 5) the long-term effects of prenatal opioid exposure on children. Workshop participants identified key scientific opportunities to advance the understanding of opioid use disorders in pregnancy and to improve outcomes for affected women, their children, and their families. This article provides a summary of the workshop presentations and discussions.
Topic(s):
Healthcare Disparities See topic collection
,
Opioids & Substance Use See topic collection
6940
Opioid Use in Pregnancy: A Review
Type: Journal Article
Authors: K. S. Ryan, K. C. Prewitt, S. Hayer, M. A. Hedges, A. E. Benson, J. O. Lo
Year: 2023
Abstract:

IMPORTANCE: The use and misuse of opioids in pregnancy have been increasing and are a major public health issue. Opioid use in pregnancy and during lactation has been associated with increased maternal and neonatal morbidity and mortality. OBJECTIVE: This review aims to summarize the existing literature and current recommendations for opioid use while pregnant or lactating. EVIDENCE ACQUISITION: A PubMed, Cochrane Library, and Google Scholar literature search using the following terms was performed to gather relevant data: "opioids," "opioid maintenance therapy," "opioid use disorder," "suboxone," "buprenorphine," "methadone," "medication for opioid use disorder," "fetal outcomes," "perinatal outcomes," "pregnancy," "lactation," and "neonatal abstinence syndrome." RESULTS: Available studies on opioid use in pregnancy and during lactation were reviewed and support association with increased odds of maternal death, placental insufficiency, cardiac arrest, preterm birth, neonatal intensive care unit admission, low birth weight, and small for gestational age infants. Studies were also reviewed on pharmacotherapy options in pregnancy and promising prenatal care models. CONCLUSION AND RELEVANCE: There is a critical need for research on the effects of opioid use and related pharmacotherapy options in pregnancy. Once the adverse perinatal effects of opioid exposure are identified and well-characterized, patient education, intervention, and antenatal surveillance can be developed to predict and mitigate its impact on maternal and fetal health.

Topic(s):
Opioids & Substance Use See topic collection
,
Healthcare Disparities See topic collection
Reference Links: